UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 10, 2012

THE COOPER COMPANIES, INC.

(Exact name of registrant as specified in its charter)

Delaware	**1-8597**	**94-2657368**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

6140 Stoneridge Mall Road, Suite 590, Pleasanton, California 94588
(Address of principal executive offices)

(925) 460-3600
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

CooperVision, Inc., a subsidiary of The Cooper Companies, Inc., received a letter from the United States Food and Drug Administration regarding the Warning Letter issued on December 5, 2011. The FDA reported that it has completed an evaluation of the Company's corrective actions, and it appears the Company has addressed the violations contained in the letter.

A copy of the letter dated July 5, 2012, is attached and incorporated by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.	Description
99.1	Letter of the United States Food and Drug Administration dated July 5, 2012.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE COOPER COMPANIES, INC.

By /s/ Rodney E. Folden
Rodney E. Folden
Vice President and Corporate Controller
(Principal Accounting Officer)

Dated: July 10, 2012

INDEX TO EXHIBITS

Exhibit No.	Description
99.1	Letter of the United States Food and Drug Administration dated July 5, 2012.

Exhibit 99.1

DEPARTMENT OF HEALTH & HUMAN SERVICES

New York District
Food & Drug Administration
158-15 Liberty Avenue
Jamaica, NY 11433

July 5, 2012

Mr. John Weber
President
CooperVision, Inc.
6140 Stoneridge Mall Road
Pleasanton, CA 94588

Dear Mr. Weber:

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter NYK-2012-4 issued on December 5, 2011. Based on our evaluation of your written responses and follow-up inspection, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,

/s/ Frank Verni

LCDR Frank Verni, USPHS
Compliance Officer
FDA – New York District

O: addressee

cc: Mr. Fernando Torres
President of Americas
CooperVision, Inc.
6140 Stoneridge Mall Road
Pleasanton, CA 94588

cc: Mr. James Della Valle
Vice President of Distribution
CooperVision Inc.
180 Thruway Park Drive
West Henrietta, New York 14586-9798

cc: Ms. Bonnie Tsymbal
Director of Regulatory Affairs and Quality Assurance
CooperVision Inc.
180 Thruway Park Drive
West Henrietta, New York 14586-9798